This is a working overview of CJC-1295, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-26 and is reviewed periodically as new material appears.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
== Applications == Applications of phage display technology include determination of interaction partners of a protein (which would be used as the immobilised phage "bait" with a DNA library consisting of all coding sequences of a cell, tissue or organism) so that the function or the mechanism of the function of that protein may be determined. Phage display is also a widely used method for in vitro protein evolution (also called protein engineering). As such, phage display is a useful tool in drug discovery. It is used for finding new ligands (enzyme inhibitors, receptor agonists and antagonists) to target proteins. The technique is also used to determine tumour antigens (for use in diagnosis and therapeutic targeting) and in searching for protein-DNA interactions using specially-constructed DNA libraries with randomised segments. Recently, phage display has also been used in the context of cancer treatments - such as the adoptive cell transfer approach. In these cases, phage display is used to create and select synthetic antibodies that target tumour surface proteins. These are made into synthetic receptors for T-Cells collected from the patient that are used to combat the disease. Recently, M13 bacteriophages were genetically engineered to display an anti-GD2 single-chain variable fragment (scFv) derived from the FDA-approved antibody Dinutuximab on their pIII coat protein. The engineered phages were subsequently loaded with hundreds of photosensitizer molecules to selectively deliver the payload to GD2-positive neuroblastoma cells.
=== Female genital mutilation === The most prevalent form of non-consensual genital alteration is that of female genital mutilation. This mostly involves the partial or complete removal of the vulva. Female genital mutilation is carried out in thirty countries in Africa and Asia with more than 200 million girls being affected, and some women (as of 2018). Nearly all of the procedures are carried out on young girls. The practices are also carried out globally among migrants from these areas. Female genital mutilation is claimed to be mostly carried out for cultural traditional reasons. According to the research conducted under In the Name of Tradition, FGM/C is more common in Sunni countries and less common in Shia societies. FGM/C can have harmful effects on their physical and mental health. Various official and unofficial research reports also confirm these complications. In its various reports, the World Health Organization has considered FGM/C as an action that endangers women's health in various ways. This organization stated in a report published in January 2023 that FGM/C has no health benefits, and it harms girls and women in many ways. It involves removing and damaging healthy and normal female genital tissue, and it interferes with the natural functions of girls' and women's bodies. Although all forms of FGM/C are associated with increased risk of health complications, the risk is greater with more severe forms of FGM/C.
=== Toxin removal === Following diagnosis, rapid removal of excess leucine from the body reduces the impact of the disease on development. Some methods of toxin removal include Exchange transfusion, hemodialysis, or hemofiltration. Exchange transfusion is an option to consider because it decreases high BCAA levels without disrupting the plasma repeatedly, however after exchange the BCAA levels will increase with the tissue storage releasing BCAAs. Hemodialysis is a safe and effective way to reduce elevated BCAA levels while correcting electrolyte and acid-base imbalances in an infant. Hemodialysis can be started as soon as a diagnosis is made when it is combined with dietary feeds that maintain recommended calorie and amino acid intake.
The overall life expectancy in Colombia at birth is 79.3 years (76.7 years for males and 81.9 years for females). Healthcare reforms have led to massive improvements in the healthcare systems of the country, with health standards in Colombia improving very much since the 1980s. The new system has widened population coverage by the social and health security system from 21% (pre-1993) to 96% in 2012. In 2017, the government declared a cancer research and treatment center as a Project of National Strategic Interest. A 2016 study conducted by América Economía magazine ranked 21 Colombian health care institutions among the top 44 in Latin America, amounting to 48 percent of the total. In 2022, 26 Colombian hospitals were among the 61 best in Latin America (42% total). Also in 2023, two Colombian hospitals were among the top 75 of the world.
Sources: en.wikipedia.org
labelling Also tagging. The chemical attachment of a highly selective substance, known as a label, tag, or probe, to a particular cell, protein, amino acid, or other molecule of interest, either naturally or artificially, in vivo or in vitro. Natural labelling is a primary mechanism by which biomolecules specifically identify and interact with other biomolecules; important examples include methylation, acetylation, phosphorylation, and glycosylation. Labelling is also a common laboratory technique, where the label is typically a reactive derivative of a naturally fluorescent compound (e.g. green fluorescent protein), dye, enzyme, antibody, radioactive molecule, or any other substance that makes its target distinguishable in some way. The labelled targets are thereby rendered distinct from their unlabelled surroundings, allowing them to be detected, identified, quantified, or isolated for further study.
Regardless of changes leading to a semantic containment mechanism in new organisms, any novel biochemical systems still has to undergo a toxicological screening. XNA, novel proteins, etc. might represent novel toxins, or have an allergic potential that needs to be assessed.
=== COVID-19 === In 2020, the monoclonal antibody therapies bamlanivimab/etesevimab and casirivimab/imdevimab were given emergency use authorizations by the US Food and Drug Administration to reduce the number of hospitalizations, emergency room visits, and deaths because of COVID-19. In September 2021, the Biden administration purchased US$2.9 billion worth of Regeneron monoclonal antibodies at $2,100 per dose to curb the shortage. As of December 2021, in vitro neutralization tests indicate monoclonal antibody therapies (with the exception of sotrovimab and tixagevimab/cilgavimab) were not likely to be active against the Omicron variant. Over 2021–22, two Cochrane reviews found insufficient evidence for using neutralizing monoclonal antibodies to treat COVID-19 infections. The reviews applied only to people who were unvaccinated against COVID‐19, and only to the COVID-19 variants existing during the studies, not to newer variants, such as Omicron. In March 2024, pemivibart, a monoclonal antibody drug, received an emergency use authorization from the US FDA for use as pre-exposure prophylaxis to protect certain moderately to severely immunocompromised individuals against COVID-19.
Peptide hormones are hormones composed of peptide molecules. These hormones influence the endocrine system of animals, including humans. Most hormones are classified as either amino-acid-based hormones (amines, peptides, or proteins) or steroid hormones. Amino-acid-based hormones are water-soluble and act on target cells via second messenger systems, whereas steroid hormones, being lipid-soluble, diffuse through plasma membranes to interact directly with intracellular receptors in the cell nucleus. Like all peptides, peptide hormones are synthesized in cellsfrom amino acids based on mRNA transcripts, which are derived from DNA templates inside the cell nucleus. The initial precursors, known as preprohormones, undergo processing in the endoplasmic reticulum. This includes the removal of the N-terminal signal peptide and, in some cases, glycosylation, yielding prohormones. These prohormones are then packaged into secretory vesicles, which are stored and released via exocytosis in response to specific stimuli, such as an increase in intracellular Ca2+ and cAMP levels. Prohormones often contain extra amino acid sequences necessary for proper folding but not for hormonal activity. Specific endopeptidases cleave the prohormone before secretion, producing the mature, biologically active hormone. Once in the bloodstream, peptide hormones travel throughout the body and bind to specific receptors on target cell membranes.
Although Mexican authorities often distinguish between homicides linked to organized crime and those that are not, the conflict has strained state resources and created an environment of impunity that has worsened crime overall. In 2009, the Mexican attorney general's office claimed that 9 of 10 victims of the Mexican drug war are members of organized crime groups, although other sources have questioned this figure. Deaths among military and police personnel are an estimated 7% of the total. The states that suffer from the conflict the most are Baja California, Guerrero, Chihuahua, Michoacán, Tamaulipas, Nuevo León, and Sinaloa.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.